A Phase 2/3 interventional study of PRGF and placebo in Achilles Tendon Tear, sponsored by Meir Medical Center. Completed. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-10-24.
Sponsored by Meir Medical Center · Phase 2/3, Interventional, and Treatment
To review the influence of patient derived PRGF on the healing process of Achilles tendon after a surgical correction of a complete tear.
Autologous platelet-rich matrices may aid in post surgical patients by promoting and accelerating tissue healing because of the release of growth factors including transforming growth factor (TGF)-beta1 and platelet-derived growth factor (PDGF) from platelet alpha-granules.
Meir Medical Center is the lead sponsor of 389 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
PRGF
Biological: PRGF
Biological: placebo
injection of 6cc into injured area of tendon
Also known as: platelet-derived preparation rich in growth factors
injection of 6 cc of saline into injured area
Also known as: saline 0.9% nacl
improvement of symptoms / disease progress
Time frame: 1 year
No study locations are listed for this record.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meir Medical Center